Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System cut its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 42.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 53,600 shares of the company's stock after selling 38,800 shares during the period. Louisiana State Employees Retirement System's holdings in Hims & Hers Health were worth $1,584,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of HIMS. US Bancorp DE grew its position in shares of Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after acquiring an additional 1,508 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in Hims & Hers Health in the 4th quarter worth about $67,000. Victory Capital Management Inc. boosted its holdings in Hims & Hers Health by 1.9% in the 4th quarter. Victory Capital Management Inc. now owns 52,579 shares of the company's stock worth $1,271,000 after buying an additional 1,002 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Hims & Hers Health by 51.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 17,225 shares of the company's stock worth $417,000 after buying an additional 5,885 shares during the last quarter. Finally, Amundi boosted its holdings in shares of Hims & Hers Health by 49.1% during the 4th quarter. Amundi now owns 12,741 shares of the company's stock worth $328,000 after purchasing an additional 4,197 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HIMS. Morgan Stanley restated an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Truist Financial boosted their target price on Hims & Hers Health from $45.00 to $48.00 and gave the stock a "hold" rating in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $39.83.

Hims & Hers Health Stock Up 0.7%

NYSE HIMS traded up $0.37 on Friday, reaching $50.36. The stock had a trading volume of 22,023,014 shares, compared to its average volume of 24,108,672. The firm has a market capitalization of $11.27 billion, a price-to-earnings ratio of 72.99, a P/E/G ratio of 1.91 and a beta of 2.02. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The stock has a fifty day moving average price of $53.86 and a two-hundred day moving average price of $41.62.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm's quarterly revenue was up 110.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.05 earnings per share. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $47.70, for a total value of $552,413.70. Following the completion of the transaction, the chief financial officer owned 54,084 shares in the company, valued at $2,579,806.80. The trade was a 17.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Andrew Dudum sold 65,110 shares of the business's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $59.22, for a total transaction of $3,855,814.20. Following the completion of the transaction, the chief executive officer owned 95,105 shares of the company's stock, valued at approximately $5,632,118.10. This trade represents a 40.64% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 633,126 shares of company stock valued at $33,717,663 over the last quarter. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.